Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSD | A5PKW4 | 4/20 | 0.51 |
| ▸ | ARF6 | P62330 | 9/20 | 0.49 |
| ▸ | PLAT | P00750 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084661 | 0.90 | ARF6 (0.52) | PSDARF6PLATMEN1LMNA | |
| SCHEMBL19084566 | 0.84 | PSD (0.52) | PSDARF6PLAT | |
| SCHEMBL19084681 | 0.82 | PSD (0.51) | PSDARF6PLATMAPTMEN1 | |
| SCHEMBL10275640 | 0.80 | ARF6 (0.53) | PSDARF6PLAT | |
| SCHEMBL31468422 | 0.79 | PLAT (0.41) | PSDARF6PLATPDE4D | |
| SCHEMBL19084609 | 0.79 | PSD (0.48) | PSDARF6PLATPDE4D | |
| SCHEMBL19084517 | 0.78 | PSD (0.49) | PSDARF6PLAT | |
| SCHEMBL19084619 | 0.78 | ARF6 (0.52) | PSDARF6PLATMAPTMEN1 | |
| SCHEMBL19084510 | 0.76 | PSD (0.51) | PSDARF6PLATPDE4D | |
| SCHEMBL19084587 | 0.73 | PSD (0.53) | PSDARF6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | NAVIGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885PLAT 3989/4885 |
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885PLAT 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.